Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer

36Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Nivolumab has promising efficacy for treating various advanced malignant tumors, although it has been reported to induce a wide range of autoimmune adverse effects. We herein report the case of a patient with metastatic lung adenocarcinoma who developed adrenal insufficiency after 12 cycles of nivolumab treatment. Endocrine test results supported a diagnosis of isolated adrenocorticotropic hormone deficiency due to hypophysitis, and replacement therapy using hydrocortisone has been successful. Although hypophysitis is a rare immune-related adverse event that is associated with nivolumab therapy, clinical awareness is essential, as this condition can be life-threatening and requires prompt treatment.

Cite

CITATION STYLE

APA

Takaya, K., Sonoda, M., Fuchigami, A., & Hiyoshi, T. (2017). Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer. Internal Medicine, 56(18), 2463–2469. https://doi.org/10.2169/internalmedicine.8548-16

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free